



PHYTORELIEF®-CC

NATURAL IMMUNITY BOOST



- No Added Gluten -
- No Added Wheat -
- No Sugar -



Proven Efficacy

PHYTORELIEF®-CC: Prevention of Cold Episodes, Control of Signs / Symptoms & Complications

Luzzi R, Belcaro G, Pellegrini L, Cornelli U, Feragalli B, Dugall M, Irvine Labs, Dept Sc Med Or Biotec, Ch-Pe University

Internationally published clinical study on patients suffering from cold episodes with PHYTORELIEF®-CC shows:


70%
Reduction in frequency of cold episodes

37%
Reduction in duration of cold episodes

43%
Reduction in number of sick days

To see full clinical, log on to: www.alchemlife.com/us

Relief from cold episodes



Minerva Gastroenterol Dietol. Oct. 2015.

ABSTRACT

The aim of this supplement, registry study was to evaluate the effects of the use of standardized, oral supplement (PHYTORELIEF®-CC, Alchem). PHYTORELIEF®-CC includes anti-inflammatory, anti-oxidant, anti-viral, immuno-modulatory, analgesic and anti-edema natural compounds. Increased salivation produced by ginger is useful in the prevention of cold episodes & signs/symptoms associated to the episodes by increasing saliva and its content (i.e. lysozyme). Main targets of the study were the evaluation of the occurrence of episodes and the reduction of signs/symptoms, the reduction of days of disease, the reduction in the use of other treatments and the control of cold-related complications.

RESULTS

The two resulting registry groups were comparable. There were 5 full episodes (lasting at least 3 days) of cold in 61 registry subjects (8.1%) in comparison with 17 cases in 63 subjects (26.98%) in controls. PHYTORELIEF®-CC subjects - even in this time-limited and small study population registry - had 30.1% of the episodes of the control group with a reduction of 69.88% of the cold episodes (p<0.0221). Also in the following, continuation, third week only 3 episodes of cold were recorded in the PHYTORELIEF®-CC group vs 6 (50% reduction) observed in controls. All the other chosen parameters were better in the supplement group (p<0.05). Affected days (2.9;1.1 vs 4.6; 1.2 in controls), lost working days (0.58;0.5 vs 1.02;0.43) in controls. The use of any other OTC product, nasal drops, aspirin, Vit C, antihistamines, aerosols, the number of complications after 4 days were better in the PHYTORELIEF®-CC group. Disease 'extension' (to >4 days), particularly tracheal and bronchial extension were significantly less frequent (p<0.05) with the supplement. No safety or tolerability problem was observed.

CONCLUSION

In conclusion this preliminary study indicates that PHYTORELIEF®-CC helps the evolution of cold if used early, when initial symptoms can be identified.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. *Based on prefactory data



PHYTORELIEF®-CC

NATURAL IMMUNITY BOOST



- No Added Gluten -
- No Added Wheat -
- No Sugar -



Proven Efficacy

PHYTORELIEF®-CC in Prevention of Flu and Cold: A 4 to 6 month Registry Study


Luzzi R., Hu S., Belc aro G.Irvine3 labs dpt Sc Med Or Biotec, Ch-Pe University

Internationally published clinical study in prevention of Flu & Cold with PHYTORELIEF®-CC shows:

- 43% Lesser occurrence of cold episodes
- 42% Lesser duration of disease
- 59% Reduction in number of sick days
- 41% Lesser use of other medications

To see full clinical, log on to: www.alchemlife.com/us

Relief from occurrence and duration of cold episodes



International Journal of Pharma Standard (ps) Supplements, 2016

ABSTRACT

The aim of this supplement, registry study was to evaluate the effects of the use of standardized, oral supplement (PHYTORELIEF®-CC, Alchem). PHYTORELIEF®-CC includes anti-inflammatory, anti-oxidant and anti-edema natural compounds. Increased salivation produced by curcumin and ginger is useful in the prevention of cold episodes and on signs and symptoms associated to the episodes by increasing saliva and its content in lysozyme. The main targets of the study were the evaluation of the occurrence of episodes and the reduction of signs/symptoms, the reduction of days of disease, the reduction in the use of other treatments and the evaluation and control of cold related complications.

RESULTS

Two groups were formed: Standard Management and Standard Management + PHYTORELIEF®-CC. Standard management to prevent flu was considered avoiding obvious sources of contamination, washing hands after contacts, using 1 g /day of Vitamin C, a healthy lifestyle, exercise, avoiding – if, when possible – closed spaces with many individuals in winter. The two resulting registry groups were comparable. The number of episodes (lasting more than 3 days), the total number of subjects with any episode, the episodes in the first and in the third week (without prevention) were all in favor of the preventive supplement. The average number of days and the lost working days were inferior with PHYTORELIEF®-CC.

CONCLUSION

In conclusion this extended preliminary study indicates that PHYTORELIEF®-CC prevents some episodes of cold and flu and helps (shortening) the evolution of cold if used early, when initial symptoms could be identified.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. *Based on prefatory data



PHYTORELIEF®-CC

NATURAL IMMUNITY BOOST



- No Added Gluten -
- No Added Wheat -
- No Sugar -



Proven Efficacy

PHYTORELIEF®-CC in Flu and Cold: A 3-Month Registry Study in Immunocompromised Patients


DUGALL M., Luzzi R., Hu S., Belc aro G.Irvine3 labs dpt Sc Med Or Biotec, Ch-Pe University

Internationally published clinical study immunocompromised patients with PHYTORELIEF®-CC shows:

- 56%** Lesser occurrence of cold episodes
- 11%** Lesser duration of disease
- 18%** Reduction in lost working days due to cold, cough & flu
- 53%** Lesser use of other treatment

To see full clinical, log on to: www.alchemlife.com/us

Reduction in cold episodes in immunocompromised patients



International Journal of Pharma Standard (jps) Supplements, 2016

ABSTRACT

The aim of this supplement, registry study was to evaluate the effects of the use of standardized, oral supplement (PHYTORELIEF®-CC, Alchem) in the prevention of cold in immunocompromised patients. PHYTORELIEF®-CC includes anti-inflammatory, anti-oxidant and anti-edema natural compounds. The main targets of the study were the evaluation of the occurrence of cold episodes and the reduction of signs/symptoms, the reduction of days of disease, the reduction in the use of other treatments and the evaluation and control of cold-related complications. The registry involved immunocompromised subjects (after chemotherapy and radiotherapy for tumors).

RESULTS

The two resulting registry groups were comparable. The number of episodes (lasting more than 3 days), the total number of subjects with any episode, the episodes in the first week (without prevention) were all in favor of the preventive supplement. The average number of days and the lost working days were also lower with PHYTORELIEF®-CC. Also the use of other OTC products and the number of complications after 4 days were significantly lower with PHYTORELIEF®-CC. Finally, the number of subjects with an extension of the diseased condition to more than 7 days with bronchial or tracheal complications was also lower with PHYTORELIEF®-CC.

CONCLUSION

In conclusion this preliminary study in immunocompromised subjects indicates that PHYTORELIEF®-CC helps prevents some episodes of cold and helps (by shortening them) the evolution of cold if used early, when initial symptoms are identified.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. **Based on prefactory data



PHYTORELIEF[®]-CC

NATURAL IMMUNITY BOOST



- No Added Gluten -
- No Added Wheat -
- No Sugar -



Proven Efficacy

PHYTORELIEF[®]-CC : A Pilot Study in BEHCET'S SYNDROME


Luzzi R., Belc aro G., Hu S.Irvine3 labs, Circulation sciences Dip Sc Med Or Biot, Ch-Pe University

Internationally published clinical study in Bahcet's Syndrome patients with PHYTORELIEF[®]-CC shows:

- 74%** Reduction in size of ulcers
- 44%** Reduction in Pain due to Ulcers
- 39%** Reduction in mouth dryness

To see full clinical, log on to: www.alchemlife.com/us

Reduction in number and size of ulcers



International Journal of Pharma Standard (ps) Supplements, 2016

ABSTRACT

The aim of this study was to evaluate the effect of use of PHYTORELIEF[®]-CC in Behcet disease (Behcet's syndrome, 'silk road' disease). Behcet's syndrome is an inflammatory, multisystem, relapsing vasculitis. Behcet's syndrome is considered a rare immune-mediated small-vessel systemic vasculitis often presenting with mucous (oral) ulceration and ocular problems. 8 subjects (37.5;3.6; 5 females) with Behcet's syndrome using PHYTORELIEF[®]-CC (Alchem) were evaluated. For the oral ulcerations patients used PHYTORELIEF[®]-CC (Alchem, India) gummy tablets to dissolve slowly in the mouth 5 times/day for two weeks.

RESULTS

After 2 weeks of supplementary management with PHYTORELIEF[®]-CC a decrease in the number of ulcerations (from 14 to 4; p<0.05) was observed. Also a decrease in the apparent size of the ulcerations (-74.3%) was observed (p<0.05). All patients described a significant, subjective decrease in symptoms (mainly pain due to ulcerations), on average -44.3% (measured on a analogue, visual scale line ranging from 0 to 100) (p<0.05) and an improvement in 'dry mouth' (-39.5%) (p<0.05). Also in 6 out of 8 subjects eye dryness was subjectively improved (on a 0 to 10 symptom scale the decrease was on average from 7.4; 1.1 to 3.4; 2.1 at 2 weeks). No tolerability problems or side effects were observed during the supplementation period. A comparative sample of 6 subjects also followed for 2 weeks and using different symptomatic products (excluding corticosteroids) did not show any decrease in the number of size of the ulcers or improvements at eye level.

CONCLUSION

An apparent, significant improvement (in mouth ulcers and dryness) was observed in these subjects, who have very limited access to management options

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. *Based on prefactory data



www.alchemlife.com | info@alchemlife.com

AUSTRALIA | HONG KONG | INDIA | JAPAN | MEXICO | SPAIN | SWITZERLAND | TURKEY | UK | USA



PHYTORELIEF®-CC

NATURAL IMMUNITY BOOST



- No Added Gluten -
- No Added Wheat -
- No Sugar -




Proven Efficacy

PHYTORELIEF®-CC : A Pilot Registry in APHTHAE and APHTHOUS Stomatitis


HU S., DUGALL M.IRV INE3 LABS , DEPT SC MED OR BIOTEC, CH-PE, UNIVERSITY

Internationally published clinical study in Aphthae and Aphthous stomatitis patients with PHYTORELIEF®-CC shows:



To see full clinical, log on to: www.alchemlife.com/us

Reduction in ulcers using PHYTORELIEF®-CC



International Journal of Pharma Standard (ps) Supplements, 2016

ABSTRACT

The aim of this study was to evaluate the effect of use of PHYTORELIEF®-CC in Aphthae and Aphthous stomatitis. Mucosal mouth aphthae are minute, painful ulcers often covered by a gray or white exudate. Aphthous Stomatitis (AS) and Recurrent Aphthous Stomatitis (RAS) are very common. This study evaluated the effects of PHYTORELIEF®-CC on Aphthous Stomatitis (AS) and Recurrent Aphthous Stomatitis (RAS).

RESULTS

A group of 18 otherwise healthy subjects with AS (6) or RAS (12) were included (age 34.8;2.2) as the control group. Another group of 14 comparable subjects used the supplement PHYTORELIEF®-CC (4-6 gummy tablets/day for at least 8 days). The use of PHYTORELIEF®-CC did not cause any safety or tolerability problems. The days with symptoms were significantly decreased with PHYTORELIEF®-CC (P<0.05). Also, ulcers were visible in average of 6.5;1.1 days in controls vs only 3.2;0.6 in the PHYTORELIEF®-CC group (p<0.05). Only 3 out of 14 subjects (21.4%) in the PHYTORELIEF®-CC group could feel the ulcer at 8 days vs. 8 out of 18 (44.44%) in the control group. This corresponds to a very important 23.04% reduction even in a small sample and in a short period.

CONCLUSION

In conclusion PHYTORELIEF®-CC is a significant option in the management of mouth users.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. *Based on prefactory data



www.alchemlife.com | info@alchemlife.com

AUSTRALIA | HONG KONG | INDIA | JAPAN | MEXICO | SPAIN | SWITZERLAND | TURKEY | UK | USA



ALEU19040015
Information leaflet intended for professionals only.